DailyIQ
|
Sector:HealthcareAll sectors
Last updated 6 minutes ago

BIIB·Biogen Inc.

$.
+. (+.%)
After Hours
High
$209.64
Open
$198.26
Market Cap
30.33B
52W High
$219.72
Low
$194.67
P. Close
$208.99
P/E
22.11
52W Low
$121.05
Fwd P/E
12.63
DailyIQ Est.
$233.86
Technical Score (1D)
82
BUY
News Sentiment
68
BULLISH
Biogen’s latest earnings report, released 14.8 hours ago, showed solid quarterly results but analysts highlighted three risks that could temper the stock’s recent 14.4 % six‑month return, including slowing sales growth, rising competition in the biologics space, and potential regulatory scrutiny over pricing. The company’s valuation remains a concern as investors weigh whether the current price reflects these headwinds, which could dampen short‑term upside. In addition, a phase II failure of the Alzheimer’s drug diranersen, disclosed 15.3 hours ago, raises doubts about the drug’s efficacy and the likelihood of regulatory approval, potentially impacting future pipeline revenue. Biogen’s decision to consider advancing diranersen to phase III despite the setback will be closely watched for guidance on resource allocation and risk appetite. The appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026, signals a strengthening of legal and compliance oversight amid ongoing regulatory scrutiny, which may influence litigation strategy and compliance risk management. The new CLO’s experience could mitigate potential legal challenges, but the impact on short‑term trading remains uncertain. At the Alzheimer’s Association International Conference 2026, Biogen presented mixed results from its tau‑targeting antisense oligonucleotide trial, with the lowest dose showing modest slowing of clinical decline but the primary endpoint missed, further eroding confidence in the company’s Alzheimer’s pipeline. The combination of pipeline setbacks, competitive pressures, and regulatory concerns suggests that the stock may face continued volatility over the next 1–10 trading days. Traders should monitor the next earnings release for updated guidance on sales growth and pipeline milestones, as well as any regulatory filings related to diranersen and the tau ASO program. Additionally, watch for any updates on the new CLO’s strategy and potential litigation outcomes that could alter the company’s risk profile.
Earnings Summary
Biogen Inc. is a global biotechnology company focused on discovering and delivering therapies for neurological and neurodegenerative diseases, with core products such as TECFIDERA and TYSABRI and a pipeline that includes Alzheimer’s and Parkinson’s candidates. The company operates in the highly competitive drug manufacturers sector, where regulatory approval and market penetration are critical drivers of performance. In the most recent quarter, Biogen reported earnings per share of $3.57 against an estimate of $2.95, while revenue rose to $2.48 billion from $2.28 billion in the prior quarter, reflecting a modest acceleration in top‑line growth; the preceding quarter’s $5.47 EPS and $2.65 billion revenue also beat estimates of $3.88 and $2.64 billion, respectively, indicating a pattern of earnings beats in the last four quarters. Over the past two fiscal years, revenue has trended upward from $2.45 billion in Q4 2024 to $2.48 billion in Q1 2026, while EPS has fluctuated, dropping from $3.44 in Q4 2024 to $1.99 in Q4 2025 before climbing to $3.57 in Q1 2026, underscoring volatility but a recent rebound; the company has consistently outperformed analyst expectations in most quarters, with no reported misses in the data set. Recent news highlights a phase‑II failure of the Alzheimer’s drug diranersen, a decision to advance it to phase III, and the FDA’s supplemental approval of a subcutaneous initiation dose for Leqembi, all of which could influence future revenue streams and investor sentiment; additionally, the appointment of a new Chief Legal Officer signals a focus on regulatory compliance amid ongoing scrutiny. Investors should watch for the next earnings call for updated guidance on sales growth, pipeline milestones, and any regulatory feedback on diranersen and Leqembi, as well as potential impacts from the new CLO’s strategy on litigation risk.

EPS

EstBeatMiss
$1.05$2.30$3.55$4.80$6.05Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.12 - -
Q1'26$2.95$3.57+20.9%
Q4'25$1.63$1.99+22.4%
Q3'25$3.88$4.81+23.9%
Q2'25$3.88$5.47+41.0%
Q1'25$2.95$3.02+2.4%

Revenue

EstBeatMiss
$2.2B$2.3B$2.4B$2.6B$2.7BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.5B - -
Q1'26$2.2B$2.5B+10.2%
Q4'25$2.2B$2.3B+1.4%
Q3'25 - $2.5B -
Q2'25 - $2.6B -
Q1'25 - $2.4B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

BIIB Stock Snapshot

BIIB is currently trading at $208.92, giving Biogen Inc. a market cap of 30.33B and a P/E ratio of 22.1. Today's range spans $194.67–$209.64, with shares opening at $198.26 and moving down $0.07 (0.0%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 68/100.

Over the past year BIIB has traded between $121.05 and $219.72 - the current price is +72.6% off the 52-week low and -4.9% from the high. 45 analysts cover the stock with a Buy consensus and a mean 12-month target of $224.45 (range $157.00–$300.00), implying upside of +7.4%.

BIIB carries a BUY signal on a 82/100 technical score, trades at $208.92 (near 52-week highs), and has bullish sentiment at 68/100. At 30.33B in Healthcare market cap (P/E: 22.1), the name has scale without the index-anchor inertia of mega-cap peers - which means when the bullish momentum runs, the percentage move can be meaningfully larger. Annual range: $121.05–$219.72.

Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (82/100) and news sentiment (68/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $208.92 (near 52-week highs), BIIB's position within the $121.05–$219.72 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.